Arsenic‐induced neurotoxicity in patients with acute promyelocytic leukaemia

Zoe Loh,Michael Ashby,Ellie Van Veldhuizen,Wenlong Li,Ashlyn Chee,Winpa Aung,Yelena Lavrukhina,George Mason,Tenille Pelly,Rithin Nedumannil,Serena Kosciejew,Mridula Mokoonlall,Jonathan Lim,Georgina Calov,Llewyn Butler,Paulina Hillebrand,Ashley Beekman,Greasha Kalani Rathnasekara,Sonia Raj,Cathey Zhang,Yao Yao,Harry Iland,Andrew Grigg

DOI: https://doi.org/10.1111/bjh.19297

2024-01-12

British Journal of Haematology

Abstract:The incidence of arsenic‐induced neurotoxicity was evaluated in 487 patients with acute promyelocytic leukaemia across Australia. Any‐grade neurotoxicity occurred in 23% of patients, predominantly peripheral neuropathy. Body mass index, weight and arsenic dose were strongly associated with the development of neurotoxicity. Summary Arsenic trioxide is an essential component of therapy for acute promyelocytic leukaemia (APL) and is currently dosed on actual body weight with no upper limit. Arsenic‐induced neurotoxicity is a well‐recognised complication; however, there is uncertainty about its relationship to arsenic dose and obesity. We conducted a large multicentre retrospective study of 487 patients with APL treated with arsenic‐based therapy across 23 sites in Australia from 2008 to 2023. The primary outcome was incidence of neurotoxicity, and secondary outcomes included relationship of neurotoxicity to obesity and cumulative arsenic dose. Any‐grade neurotoxicity occurred in 113 (23%) patients, predominantly peripheral neuropathy (91%). Most events were grade 1–2 severity (85%), with grade 3 events in 12% and grade 4–5 in 3%. The incidence of neurotoxicity increased with BMI (non‐obese: 16%, obesity class I: 25%, obesity class II–III: 41%; p 100 kg (OR 2.72, p 15 mg (OR 5.05, p 500 mg (OR 3.95, p 500 mg remained significant on multivariable analysis. Our study highlights the strong association between BMI, arsenic trioxide dose and neurotoxicity. Pre‐emptive dose reductions should be considered for obese patients receiving high doses of arsenic.

hematology